lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amazing. Thank you!
Untrue.
Contingency means shareholders are not paying for the cost of litigation.
We are approaching the stage where settlement seems probable after MTD denial.
I am also fine with a settlement if commensurate with the damage endured by shareholders as well as a punitive deterrent so this behavior stops.
Can you imagine the discoveries which have been prevented due to such illegal manipulation?
The behavior damages our economy, competitiveness internationally, as well as public health.
For that reason I hope management will move forward with the lawsuit unless a very substantial $1-2B settlement, as well as public statement of wrongdoing, can be achieved at this juncture.
Market Makers must acknowledge their grievous error unless they desire their dirty laundry shown for the public to witness.
HFT has nothing to do with the lawsuit as it isn't regarding how fast orders are placed or executed but whether they're genuine orders or fraudulent.
Humans haven't traded stock in decades while we are not complaining about statistical arbitrage or any other legitimate HFT trading strategy. The issue is criminal spoofing.
I only recall seeing Linda Powers on SEC filings.
Les sold the instrument so it should be his signature though I am unsure if this was the first time he signed 10K-NT. They haven't had one since I bought the company though I know they had issues meeting deadlines in the past.
Management cannot simply lie about the reason for filing 10K-NT unless they want jailtime before imminent MHRA approval. Seems like a bad risk reward tradeoff unless you're a psychopath.
Delay filed:
Monte Carlo simulations are used in risk models to forecast future returns from various business decisions. It's a very common model used in finance. I suspect they sold some derivative at a price based upon simulation which may now not be entirely accurate perhaps due to a change in inputs to the simulation. It will be very interesting to see the upcoming 10K in next 15 days.
https://en.m.wikipedia.org/wiki/Monte_Carlo_method
Very good point. There are numerous benefits brought by Flaskworks. I hope for approval by June after MAA approved in March - April.
Forbes are garbage. The only topic for Glioblastoma should be DCVax. The journalist who wrote this arficle is a blind jackass wondering in the woods.
Combination trial useless without Flaskworks?
DCVax has achieved 98% purity with the traditional clean room process as Dr Bosch explained in his manufacturing talk at ASCO.
Another day closer to approval.
Shorts, beware the Ides of March!
I agree which is why I have the idiots on ignore.
As we know Sawston passed inspection multiple times. Linda Powers runs a tight ship. I agree there likey won't be an RFI. Many who say the opposite forgot the company’s record of delivering results, are unfamiliar with the approval process, or wish to manipulate the stock price.
No RFI then MHRA makes determination on approval. No Phase II.
Phase II exists to address issues raised in the RFI.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173934572
In my opinion NWBO submitted a complete application without error while the exemplary data speaks for itself.
Regulators have known about DCVax for over a decade.
It was approved for use on children after approval in adults.
MHRA approved its commercial manufacturing as well as export.
No side effects.
Treats orphan disease that kills MPs, the rich, poor, the young, and the elderly.
Universal fear of Glioblastoma.
Approval only in question among those without a brain!
JFC the database on this website is fucked.
Phase II is only for RFI. Those who say otherwise are wrong.
I agree the trials should begin as soon as possible.
They can use potency assays and proteomic analysis not another trial. I don't see this as being a big deal for the handful of patients that would be in PI/II trials. It didn't stop Merck from running trials with DCVax at UCLA.
Though perhaps you are correct and we may not get notice of licensing deals, partnership, or buyout until Flaskworks gets GMP approval in UK. Though I am skeptical as the value seems already apparent.
They can use potency assays and proteomic analysis not another trial. I don't see this as being a big deal for the handful of patients that would be in PI/II trial. Though perhaps you are correct and we may not get notice of licensing deals until Flaskworks gets GMP approval in UK. Though I am skeptical.
Advent can ramp up to 12000 patients a year with open clean room technology while Charles River Labs have expertise with manufacturing DCVax right now. Why would partners wait for GMP approval for Flaskworks when they're not likely to see instant off label use for DCVax against other unapproved indications? I would expect additional trials to begin with traditional clean rooms but we may have Flaskworks approval by Q3 which would increase Linda's leverage in negotiations. These are exciting times!
CRL and Advent are already GMP certified with existing clean room manufacturing. I do not think Northwest are waiting for Flaskworks. They need revenue as soon as possible. Patients need the treatment. NICE will reimburse up to 100K per QALY. Private insurance in US covers existing high cost oncology treatments. Flaskworks will be needed to meet global demand but isn't prerequisite for regulatory approval.
FDA submission seems around the corner given we have patient advocates organizing for FDA approval.
Looking forward to updates in 10K due this week.
GlassJoe is often wrong.
Phase II is optional and only needed if an RFI is issued.
DCVax approved in Phase 1. No optional RFI or CHM.
Approval March 2024.
No RFI.
No CHM.
MHRA has known about DCVax for 10 years.
No reason to delay treatment with no side effects on optional steps which are not necessary.
Beware the Ides of March all ye who hold NWBO short!
Flaskworks is 12X more productive than manual clean rooms but also smaller. So I believe Sawston will very likely have higher capacity than 144K patients per year.
I agree jfr!
Can you read my poker face?
Sale of the company requires shareholder approval. We are certainly being gaslit by shorts who want our shares.
Bought more today. Congratulations to all longs who have done the same over past few weeks!
Jackass
Roth IRA!
If you're not selling today then tomorrow only brings additional opportunity.
No doubt in my mind that organized crime of Sicilian and Russian heritage are involved in manipulating NWBO stock. The question remains how long will it take for Cofer Black to strike?